
浏览全部资源
扫码关注微信
1.450002 郑州,河南省人民医院,河南大学人民医院,郑州大学人民医院医学遗传研究所河南省遗传性疾病功能重点实验室
2.450002 郑州,河南省人民医院,河南大学人民医院,郑州大学人民医院医学遗传研究所泌尿外科
3.450002 郑州,河南省人民医院,河南大学人民医院,郑州大学人民医院医学遗传研究所肾内科
4.450002 郑州,河南省人民医院,河南大学人民医院,郑州大学人民医院医学遗传研究所神经外科
[ 王斌,E-mail:wb201166@sina.com WANG Bin, E-mail: wb201166@sina.com
收稿:2021-04-30,
修回:2021-07-06,
纸质出版:2021-10-30
移动端阅览
娄桂予, 田向永, 张玉薇, 等. 3个常染色体显性遗传多囊肾病家系的遗传学分析[J]. 第三军医大学学报, 2021,43(20):2208-2213.
Guiyu LOU, Xiangyong TIAN, Yuwei ZHANG, et al. Genetic analysis of 3 pedigrees with autosomal dominant polycystic kidney disease[J]. Journal of Third Military Medical University, 2021, 43(20): 2208-2213.
娄桂予, 田向永, 张玉薇, 等. 3个常染色体显性遗传多囊肾病家系的遗传学分析[J]. 第三军医大学学报, 2021,43(20):2208-2213. DOI: 10.16016/j.1000-5404.202104203.
Guiyu LOU, Xiangyong TIAN, Yuwei ZHANG, et al. Genetic analysis of 3 pedigrees with autosomal dominant polycystic kidney disease[J]. Journal of Third Military Medical University, 2021, 43(20): 2208-2213. DOI: 10.16016/j.1000-5404.202104203.
目的
2
对3个常染色体显性遗传多囊肾病家系进行基因检测,明确其致病性突变,为防治方法及产前诊断提供指导。
方法
2
收集2017-2020年在河南省人民医院泌尿外科就诊的3个多囊肾家系的病史及临床资料;采集家系成员外周血样品提取DNA,利用靶向扩增高通量测序方法对先证者进行检测,筛查可疑致病位点;Sanger测序法对先证者及家系其他成员进行验证及分析,结合生物信息学分析及美国医学遗传与基因组学会制定的基因变异致病性评估标准,分析变异的致病性。
结果
2
家系1、2、3先证者超声结果诊断均为多囊肾,临床分期分别为G1、G3a和G5,在
PKD
1(polycystic kidney disease 1)基因分别发现c.5933delA(p.Asn1978fs)缺失移码突变、c.6871C
>
T(G2291X)无义杂合突变和c.894_897delCCCT(p.299Sfs*34)缺失移码变异。3个家系的以上变异符合表型-基因型相分离。
结论
2
明确了遗传多囊肾病3个家系的致病变异位点,其中c.5933delA和c.894_897delCCCT为新突变,c.6871C>T为已知致病性突变。
Objective
2
To clarify the pathogenic mutations and provide references for prevention and treatment strategies and prenatal diagnosis by gene detection in 3 pedigrees with autosomal dominant polycystic kidney disease (ADPKD).
Methods
2
The family history and clinical data of 3 ADPKD pedigrees who admitted to our department of urology during 2017 and 2020 were collected in this study. The peripheral blood samples of these family members were harvested for DNA extraction. Targeted amplification and high-throughput sequencing was used to screen suspected pathogenic mutations in probands
and then these obtained mutations were verified and analyzed in the probands and their family members by Sanger sequencing. The pathogenicity of these mutations was analyzed with bioinformation analysis and the evaluation criteria of the American Society of Medical Genetics.
Results
2
Ultrasound examination showed that all the probands from the 3 families had polycystic kidneys
at the clinical stages of G1
G3a
and G5 respectively. The deletion frameshift mutation c.5933delA (p.Asn1978fs)
nonsense heterozygous mutation c.6871C
>
T (G2291X) and deletion frameshift mutation of c.894_897delCCCT (p.299Sfs*34) in polycystic kidney disease 1 (
PKD
1) gene were detected in pedigrees 1
2 and 3
respectively. The above variants in the 3 families were in line with phenotype-genotype separation.
Conclusion
2
We identify the pathogenic variants in the 3 pedigrees of hereditary polycystic kidney disease
among which c.5933delA and c.894_897delCCCT are new mutations
and c.6871C>T is a known pathogenic mutation.
CORNEC-LE GALL E, AUDRÉZET M P, LE MEUR Y, et al . Genetics and pathogenesis of autosomal dominant pol ycystic kidney disease: 20 years on[J ] . Hum Mutat, 2014, 35(12): 1393-1406. DOI: 10.1002/humu.22708.
BERGMANN C, GUAY-WOODFORD L M, HARRIS P C, et al . Polycystic kidney disease[J ] . Nat Rev Dis Primers, 2018, 4(1): 50. DOI: 10.1038/s41572-018-0047-y.
NOBAKHT N, HANNA R M, AL-BAGHDADI M, et al . Advances in autosomal dominant polycystic kidney disease: a clinical review[J ] . Kidney Med, 2020, 2(2): 196-208. DOI: 10.1016/j.xkme.2019.11.009.
BRAUN W E. Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments[J]. Cleve Clin J Med, 2009, 76(2): 97-104. DOI: 10.3949/ccjm.76a.gr001.
徐德超, 马熠熠, 梅长林. 托伐普坦治疗快速进展型常染色体显性多囊肾病的临床实践指南解读[J]. 中华肾脏病杂志, 2019, 35 (5): 387-392. DOI: 10.3760/cma.j.issn.1001-7097.2019.05.011.
XU D C, MA Y Y, MEI C L. Interpretation of the clinical practice guideline for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan[J]. Chin J Nephrol, 2019, 35(5): 387-392. DOI: 10.3760/cma.j.issn.1001-7097.2019.05.011.
TORRES V E, HARRIS P C. Progress in the understanding of polycystic kidney disease[J]. Nat Rev Nephrol, 2019, 15(2): 70-72. DOI: 10.1038/s41581-018-0108-1.
PALYGIN O, ILATOVSKAYA D V, LEVCHENKO V, et al . Characterization of purinergic receptor expression in ARPKD cystic epithelia[J ] . Purinergic Signal, 2018, 14(4): 485-497. DOI: 10.1007/s11302-018-9632-5.
LEUNG J. Inherited renal diseases[J]. Curr Pediatr Rev, 2014, 10(2): 95-100. DOI: 10.2174/157339631002140513101755.
XUE C, ZHOU C C, WU M, et al . The clinical manifestation and management of autosomal dominant polycystic kidney disease in China[J ] . Kidney Dis (Basel), 2016, 2(3): 111-119. DOI: 10.1159/000449030.
胡胜, 李东杰, 谭新骥, 等. 常染色体显性遗传多囊肾病的研究进展[J]. 中南大学学报(医学版), 2019, 44(10): 1179-1187. DOI: 10.11817/j.issn.1672-7347.2019.180110.
HU S, LI D J, TAN X J, et al . Research progress in autosomal dominant polycystic kidney disease[J ] . J Central South Univ Med Sci, 2019, 44(10): 1179-1187. DOI: 10.11817/j.issn.1672-7347.2019.180110.
GRANTHAM J J, CHAPMAN A B, BLAIS J, et al . Tolvapt an suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease[J ] . Nephrol Dial Transplant, 2017, 32(6): 969-975. DOI: 10.1093/ndt/gfw060.
GRANTHAM J J. Autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2008, 359(14): 1477-1485. DOI: 10.1056/nejmcp0804458.
SU Q, HU F Z, GE X F, et al . Structure of the human PKD1-PKD2 complex[J ] . Science, 2018, 361(6406): eaat9819. DOI: 10.1126/science.aat9819.
王秋菊, 沈亦平, 邬玲仟, 等. 遗传变异分类标准与指南[J]. 中国科学: 生命科学, 2017, 47(6): 668-688.
WANG Q J, SHEN Y P, WU L Q, et al . Classification criteria and guidelines for genetic variation[J ] . Sci Sin Vitae, 2017, 47(6): 668-688.
HWANG Y H, CONKLIN J, CHAN W, et al . Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease[J ] . J Am Soc Nephrol, 2016, 27(6): 1861-1868. DOI: 10.1681/ASN.2015060648.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621